Bio-Techne to Be Acquired by Merck KGaA in Deal Valued at $11.3 Billion
Merck KGaA entered into a definitive agreement to acquire Bio-Techne for $73 per share, representing an enterprise value of $11.3 billion. This transaction is expected to immediately accretive to sales growth and EBITDA, strengthening Merck's presence in the life sciences market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day